Laboratory Members



Discover Walk for the Beckman Center


New York Times: June 22, 1993:

Scientists Decipher Mysterious Process of Signaling in Cells.

By Gina Kolata
An article in the Science Section of the New York Times describing the work done in the Crabtree and Schreiber labs that lead to an understanding of the Ca2+/calcineurin/NF-AT signaling pathway and the mechanism of action of cyclosporin A and FK506.....more

New York Times: September 3, 1996

A Molecule that Switches Genes On and Off

by Gina Kolata.
A summary of the development of synthetic ligands or CID’s and their use to activate and inactivate transcription by David Spencer, Steffan Ho and others in the Crabtree and Schreiber labs. Note the shape of the receptors in the diagram used in the article...more

Discovery Magazine: February 1996:

Conversations in a Cell,

by Gary Taubes
More on the discovery of the mechanism of action of CsA and the development of synthetic ligands in the Crabtree and Schreiber labs.

Wall Street Journal: January 1999

An article summarizing the successful use of synthetic ligands to activate transcription of EPO in monkeys and mice. The work was done at Ariad in collaboration with Jim Wilson and uses the system for transcriptional activation developed by Steffan Ho (Nature 382, 822 1996)

New York Times, February 23, 1999:

Gene Therapy Passes Important Tests in Monkeys.
by Nicholas Wade
An article in the summarizing the use of synthetic ligands for regulated gene therapy in monkeys using the system developed by Stephan Ho and Steve Biggar in the laboratory (Nature 382, 822 1996). The article highlights the studies of Jim Wilson at the University of Penn and Mike Gilman at Ariad.

BBC News, Oct 29th 2004 pdf

Molecule Offers Alzheimer's Hope

A brief report on Isabella Graef's and Jason Gastwicki's Science paper appearing on the same date and earlier work by Roger Breisiwitz in the lab demonstating a new strategy for making drugs. We call these Trojan Horse molecules because they diffuse into the cell and then bind very tightly to an endogenous protein generating a complex with sufficient steric bulk and surface area to block the continued aggregation of A-beta peptide from Amyloid A protein. Aggregates of these peptides are toxic and hence preventing their aggregation prevents toxicity to neurons. Similar brief reports on this work were published by CNN news, CBS and Scientific American.

BBC News, Oct 8th, 2006

New Way to Build Stronger Bones

A brief report on Monte Winslow's discovery that slightly shifting the nuclear dwell time of NFATc1 in developing mice results in a drastic increase in bone density. The work, which was published in Developmental Cell suggest that small molecules that inhibit the NFAT export kinases might be useful drugs or at least leads for treatment of osteoporosis. more

Wall Street Journal, May 10th 2006

An article covering the use of Protein C for treatment of septic shock. Human Protein C was first cloned by Jorge Plutzky, a student in the Crabtree laboratory, who is now Associate Professor of Medicine at Harvard. Protein C is a critical regulator of both the innate immune response and the coagulation pathway. Jerry became interested in it because of its genetically dominant role in human disease. Scientist at Eli Lilly used the clone isolated in the Crabtree laboratory and developed Protein C to a useful drug and demonstrated its effectiveness in treatment of septic shock. It was FDA approved in 2002. It is now the only effective therapy for this disorder and reported to save 50,000 lives per year by Lilly's CEO, Sidney Taurel. More and associated New York Times article.














  Design and Content by G R Crabtree